Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell Culture

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    293 result(s) found for: Cell Culture. Displaying page 1 of 15.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-005929-49 Sponsor Protocol Number: VX11-787-101 Start Date*: 2012-02-20
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2a, Randomized, Double Blind, Placebo Controlled Study to Investigate the Effects of VX 787 Administered to Adult Volunteers Experimentally Inoculated with Live Influenza Virus
    Medical condition: Influenza A
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022002 Influenza A virus infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001534-13 Sponsor Protocol Number: V58P12 Start Date*: 2007-11-08
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Combined Phase II/III, Observer-Blind, Randomized, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cel...
    Medical condition: Healthy pediatric population from 3-17 years
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004854-97 Sponsor Protocol Number: A8851019 Start Date*: 2008-01-15
    Sponsor Name:Pfizer Ltd
    Full Title: OPEN-LABEL, NON-COMPARATIVE, STUDY OF INTRAVENOUS ANIDULAFUNGIN, FOLLOWED OPTIONALLY BY ORAL VORICONAZOLE OR FLUCONAZOLE THERAPY, FOR TREATMENT OF DOCUMENTED CANDIDEMIA/INVASIVE CANDIDIASIS IN INTE...
    Medical condition: CANDIDAEMIA/INVASIVE CANDIDIASIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064954 Invasive candidiasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FR (Completed) BE (Completed) PT (Completed) NL (Completed) IT (Completed) SK (Completed) PL (Completed) CZ (Completed) DK (Completed) HU (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001699-43 Sponsor Protocol Number: BPR-CS-009 Start Date*: 2018-12-13
    Sponsor Name:Basilea Pharmaceutica International Ltd
    Full Title: A randomized, double-blind, multi-center study to establish the efficacy and safety of ceftobiprole medocaril compared to daptomycin in the treatment of Staphylococcus aureus bacteremia, including ...
    Medical condition: Complicated staphylococcus aureus bacteremia (cSAB)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004862 10058887 Staphylococcus aureus bacteremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BG (Completed) ES (Completed) IT (Completed) GR (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004804-38 Sponsor Protocol Number: 073-202 Start Date*: 2011-12-13
    Sponsor Name:ViroDefense Inc
    Full Title: A Randomized, Blinded, Placebo-Controlled, Poliovirus Challenge Study To Evaluate The Therapeutic Efficacy, Safety, Tolerability And Pharmacokinetics Of Orally Administered V-073 In Healthy Adult V...
    Medical condition: Poliomyelitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10036017 Poliomyelitis viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017939-18 Sponsor Protocol Number: 08/0316 Start Date*: 2010-12-15
    Sponsor Name:University College London
    Full Title: A Phase 4 randomised, double-blind, placebo controlled, crossover trial Nitrofurantoin Macrocrystals 100 mg twice daily for six weeks in the treatment of overactive bladder symptoms associated w...
    Medical condition: Chronic urinary tract infection.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002690-35 Sponsor Protocol Number: OEV123 Start Date*: 2017-05-08
    Sponsor Name:Scandinavian Biopharma AB
    Full Title: A randomized, placebo-controlled phase IIb (OEV 123) study to evaluate safety, immunogenicity, diagnostic methodology, and estimate vaccine efficacy of an oral enterotoxigenic Escherichia coli (ET...
    Medical condition: Healthy voluteers (prevention of diarrheal disease due to infection with enterotoxigenic E. coli [ETEC])
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10054242 Escherichia coli infection LLT
    19.1 100000004862 10044552 Traveller's diarrhea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2016-002883-15 Sponsor Protocol Number: V130_12 Start Date*: 2017-07-19
    Sponsor Name:Seqirus UK Limited
    Full Title: A Phase III/IV, Stratified, Randomized, Observer Blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine C...
    Medical condition: Profylaxis for Influenza virus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) ES (Completed) FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002192-23 Sponsor Protocol Number: GS-US-404-1808 Start Date*: 2016-06-03
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2b, Dose-Ranging Study of the Effect of GS-5745 on FEV1 in Adult Subjects with Cystic Fibrosis
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001223-13 Sponsor Protocol Number: V58_31 Start Date*: 2014-12-03
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Phase III, Observer-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture or in Embryonated Ch...
    Medical condition: Prophylaxis: Influenza
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-003772-31 Sponsor Protocol Number: IT001-302 Start Date*: 2018-12-07
    Sponsor Name:Iterum Therapeutics International Limited
    Full Title: A prospective, Phase 3, randomized, multi-center, double-blind, double dummy study of the efficacy, tolerability and safety of intravenous sulopenem followed by oral sulopenem-etzadroxil with probe...
    Medical condition: Complicated urinary tract infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) EE (Ongoing) CZ (Completed) BG (Completed) SK (Completed) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004261-10 Sponsor Protocol Number: AR-105-002 Start Date*: 2017-10-19
    Sponsor Name:Aridis Pharmaceuticals, Inc.
    Full Title: Placebo-controlled, double-blind, randomized study of Aerucin® as adjunct therapy to antibiotics in the treatment of P. aeruginosa pneumonia
    Medical condition: Pseudomonas aeruginosa pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10035664 Pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) CZ (Completed) HU (Completed) ES (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001857-29 Sponsor Protocol Number: V130_14 Start Date*: 2019-03-13
    Sponsor Name:Seqirus UK Limited
    Full Title: A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to...
    Medical condition: Prophylaxis of influenza virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BG (Completed) EE (Completed) CZ (Completed) LV (Completed) PL (Completed) Outside EU/EEA RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003369-20 Sponsor Protocol Number: CT-P59_3.2 Start Date*: 2020-11-13
    Sponsor Name:Celltrion, Inc
    Full Title: A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute R...
    Medical condition: SARS CoV 2 infection in outpatients
    Disease: Version SOC Term Classification Code Term Level
    23.0 10022891 - Investigations 10084271 SARS-CoV-2 test positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) RO (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000468-27 Sponsor Protocol Number: BVX-010 Start Date*: 2018-07-04
    Sponsor Name:BiondVax Pharmaceuticals Ltd.
    Full Title: A pivotal, multicentre, randomized, modified double-blind, placebo-controlled phase 3 trial to assess the safety and clinical efficacy of M-001, an influenza vaccine administered intramuscularly tw...
    Medical condition: Flu vaccination
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10016794 Flu vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) LV (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000850-36 Sponsor Protocol Number: 201600136 Start Date*: 2017-05-01
    Sponsor Name:Archivel Farma S.L.
    Full Title: Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients with Multi-Drug Resistant Tuberculos...
    Medical condition: The medical condition to be investigated is culture-confirmed Multidrug-resistant tuberculosis, i.e. tuberculosis resistant to the two first-line drugs Rifampicin and Isoniazid
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003665-10 Sponsor Protocol Number: RBH2017/001 Start Date*: 2020-02-25
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust
    Full Title: A single-centre study of the relationship between eosinophil activation and the lung microbiome in severe eosinophilic asthma (SEA) and the effect of benralizumab on these factors
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-003446-45 Sponsor Protocol Number: TBTCS31/A5349 Start Date*: 2016-02-25
    Sponsor Name:Unidad de investigación en Tuberculosis de Barcelona
    Full Title: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial
    Medical condition: Pulmonary tuberculosis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011895-31 Sponsor Protocol Number: CLIN903 LCM201 Start Date*: 2009-07-08
    Sponsor Name:STEBA BIOTECH
    Full Title: EVALUATION OF THE SAFETY AND EFFICACY OF WST11 MEDIATED VASCULAR TARGETED PHOTODYNAMIC THERAPY ON OBSTRUCTING ENDOBRONCHIAL NON-SMALL CELL LUNG CANCER
    Medical condition: Obstructive endobronchial non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016000-22 Sponsor Protocol Number: XM22-04 Start Date*: 2010-03-22
    Sponsor Name:BioGeneriX AG
    Full Title: Efficacy and safety of XM22 in patients with non small cell lung cancer receiving cisplatin / etoposide chemotherapy. A multinational, multicentre, randomised, double-blind placebo-controlled study
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10025054 Lung cancer non-small cell stage IIIB LLT
    12.0 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:45:39 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA